Authors
Paul D Brown, Stephanie Pugh, Nadia N Laack, Jeffrey S Wefel, Deepak Khuntia, Christina Meyers, Ali Choucair, Sherry Fox, John H Suh, David Roberge, Vivek Kavadi, Soren M Bentzen, Minesh P Mehta, Deborah Watkins-Bruner, Radiation Therapy Oncology Group (RTOG)
Publication date
2013/10/1
Journal
Neuro-oncology
Volume
15
Issue
10
Pages
1429-1437
Publisher
Oxford University Press
Description
Background
To determine the protective effects of memantine on cognitive function in patients receiving whole-brain radiotherapy (WBRT).
Methods
Adult patients with brain metastases received WBRT and were randomized to receive placebo or memantine (20 mg/d), within 3 days of initiating radiotherapy for 24 weeks. Serial standardized tests of cognitive function were performed.
Results
Of 554 patients who were accrued, 508 were eligible. Grade 3 or 4 toxicities and study compliance were similar in the 2 arms. There was less decline in delayed recall in the memantine arm at 24 weeks (P = .059), but the difference was not statistically significant, possibly because there were only 149 analyzable patients at 24 weeks, resulting in only 35% statistical power. The memantine arm had significantly longer time to cognitive decline (hazard ratio 0.78, 95 …
Total citations
Scholar articles
PD Brown, S Pugh, NN Laack, JS Wefel, D Khuntia… - Neuro-oncology, 2013